With 2.09 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.47 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.5 whereas the lowest price it dropped to was $1.35. The 52-week range on OGEN shows that it touched its highest point at $75.60 and its lowest point at $1.54 during that stretch. It currently has a 1-year price target of $30.00. Beta for the stock currently stands at 0.75.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of OGEN was down-trending over the past week, with a drop of -58.38%, but this was down by -71.26% over a month. Three-month performance dropped to -77.39% while six-month performance fell -89.42%. The stock lost -87.00% in the past year, while it has lost -95.38% so far this year.
Float and Shares Shorts:
At present, 0.72 million OGEN shares are outstanding with a float of 0.67 million shares on hand for trading. On 2025-06-13, short shares totaled 0.29 million, which was 4045.0000000000005 higher than short shares on 1747267200. In addition to Mr. Charles L. Pope C.P.A. as the firm’s Executive Chairman, Ms. Janet Huffman serves as its CEO, President, CFO, Secretary & Treasurer.
Institutional Ownership:
Through their ownership of 0.013150001 of OGEN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, OGEN reported revenue of $0.0 and operating income of -$2026227.0. The EBITDA in the recently reported quarter was -$2016024.0 and diluted EPS was -$0.12.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With OGEN analysts setting a high price target of 30.003 and a low target of 30.003, the average target price over the next 12 months is 30.003. Based on these targets, OGEN could surge 1983.54% to reach the target high and rise by 1983.54% to reach the target low. Reaching the average price target will result in a growth of 1983.54% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.76 being high and -$0.76 being low. For OGEN, this leads to a yearly average estimate of -$0.76.
